Drug Name |
Extendin-4 |
Drug ID |
BADD_D00863 |
Description |
Exenatide is a glucagon-like peptide-1 (GLP-1) analog[Label]. It functions to activate the GLP-1 receptor and increases insulin secretion, decrease glucagon secretion, and slow gastric emptying to improve glycemic control[Label]. Exenatide was given FDA approval on April 28, 2005[L6106]. |
Indications and Usage |
Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control. |
Marketing Status |
Prescription |
ATC Code |
A10BJ01 |
DrugBank ID |
DB01276
|
KEGG ID |
D04121
|
MeSH ID |
D000077270
|
PubChem ID |
16157882
|
TTD Drug ID |
D00YVF
|
NDC Product Code |
0406-7310; 0310-6524; 62756-040; 0310-6512; 52416-125; 0310-6530; 41524-0003; 52416-105; 69766-078; 0310-6540 |
Synonyms |
Exenatide | Bydureon | ITCA 650 | AC 2993 LAR | Exendin-4 | Ex4 Peptide | Peptide, Ex4 | Exendin 4 | Byetta | AC 2993 |